Metabolomic Profiles of Body Mass Index in the Framingham Heart Study Reveal Distinct Cardiometabolic Phenotypes

Background Although obesity and cardiometabolic traits commonly overlap, underlying pathways remain incompletely defined. The association of metabolite profiles across multiple cardiometabolic traits may lend insights into the interaction of obesity and metabolic health. We sought to investigate metabolic signatures of obesity and related cardiometabolic traits in the community using broad-based metabolomic profiling. Methods and Results We evaluated the association of 217 assayed metabolites and cross-sectional as well as longitudinal changes in cardiometabolic traits among 2,383 Framingham Offspring cohort participants. Body mass index (BMI) was associated with 69 of 217 metabolites (P<0.00023 for all), including aromatic (tyrosine, phenylalanine) and branched chain amino acids (valine, isoleucine, leucine). Additional metabolic pathways associated with BMI included the citric acid cycle (isocitrate, alpha-ketoglutarate, aconitate), the tryptophan pathway (kynurenine, kynurenic acid), and the urea cycle. There was considerable overlap in metabolite profiles between BMI, abdominal adiposity, insulin resistance [IR] and dyslipidemia, modest overlap of metabolite profiles between BMI and hyperglycemia, and little overlap with fasting glucose or elevated blood pressure. Metabolite profiles were associated with longitudinal changes in fasting glucose, but the involved metabolites (ornithine, 5-HIAA, aminoadipic acid, isoleucine, cotinine) were distinct from those associated with baseline glucose or other traits. Obesity status appeared to “modify” the association of 9 metabolites with IR. For example, bile acid metabolites were strongly associated with IR among obese but not lean individuals, whereas isoleucine had a stronger association with IR in lean individuals. Conclusions In this large-scale metabolite profiling study, body mass index was associated with a broad range of metabolic alterations. Metabolite profiling highlighted considerable overlap with abdominal adiposity, insulin resistance, and dyslipidemia, but not with fasting glucose or blood pressure traits.

[1]  Nicholette D. Palmer,et al.  Metabolomic profile associated with insulin resistance and conversion to diabetes in the Insulin Resistance Atherosclerosis Study. , 2015, The Journal of clinical endocrinology and metabolism.

[2]  E. Feskens,et al.  Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.

[3]  W. Kannel,et al.  An investigation of coronary heart disease in families. The Framingham offspring study. , 1979, American journal of epidemiology.

[4]  Christian Gieger,et al.  Novel biomarkers for pre-diabetes identified by metabolomics , 2012, Molecular systems biology.

[5]  L. Tecott,et al.  Mouse models of serotonin receptor function: toward a genetic dissection of serotonin systems. , 2000, Pharmacology & therapeutics.

[6]  V. Mootha,et al.  Metabolite profiles and the risk of developing diabetes , 2011, Nature Medicine.

[7]  Samuli Ripatti,et al.  Metabolic Signatures of Adiposity in Young Adults: Mendelian Randomization Analysis and Effects of Weight Change , 2014, PLoS medicine.

[8]  M. Laakso,et al.  Associations of multiple lipoprotein and apolipoprotein measures with worsening of glycemia and incident type 2 diabetes in 6607 non-diabetic Finnish men. , 2015, Atherosclerosis.

[9]  B. Duncan,et al.  Smoking, Smoking Cessation, and Risk for Type 2 Diabetes Mellitus , 2010, Annals of Internal Medicine.

[10]  Udo Hoffmann,et al.  Abdominal Subcutaneous and Visceral Adipose Tissue and Insulin Resistance in the Framingham Heart Study , 2010, Obesity.

[11]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[12]  Bryan C. Batch,et al.  Branched chain amino acids are novel biomarkers for discrimination of metabolic wellness. , 2013, Metabolism: clinical and experimental.

[13]  J. Shaw,et al.  Plasma lipid profiling in a large population-based cohort[S] , 2013, Journal of Lipid Research.

[14]  A. Marette,et al.  Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. , 2001, The Journal of biological chemistry.

[15]  A. Frati,et al.  Acute Effect of Cigarette Smoking on Glucose Tolerance and Other Cardiovascular Risk Factors , 1996, Diabetes Care.

[16]  L. Kaplan,et al.  Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity , 2013, International Journal of Obesity.

[17]  Svati H Shah,et al.  A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. , 2009, Cell metabolism.

[18]  T. Spector,et al.  Lipidomics Profiling and Risk of Cardiovascular Disease in the Prospective Population-Based Bruneck Study , 2014, Circulation.

[19]  Dae-Joong Kang,et al.  Bile salt biotransformations by human intestinal bacteria Published, JLR Papers in Press, November 18, 2005. , 2006, Journal of Lipid Research.

[20]  William E. Kraus,et al.  Relationships Between Circulating Metabolic Intermediates and Insulin Action in Overweight to Obese, Inactive Men and Women , 2009, Diabetes Care.

[21]  L. Heisler,et al.  Serotonin and energy balance: molecular mechanisms and implications for type 2 diabetes , 2007, Expert Reviews in Molecular Medicine.

[22]  Christian Gieger,et al.  Metabolic Footprint of Diabetes: A Multiplatform Metabolomics Study in an Epidemiological Setting , 2010, PloS one.

[23]  T. Huh,et al.  Cytosolic NADP+-dependent Isocitrate Dehydrogenase Plays a Key Role in Lipid Metabolism* , 2004, Journal of Biological Chemistry.

[24]  Cheng-chin Hsu,et al.  Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. , 2005, European Journal of Pharmacology.

[25]  Olga Ilkayeva,et al.  BMI, RQ, Diabetes, and Sex Affect the Relationships Between Amino Acids and Clamp Measures of Insulin Action in Humans , 2014, Diabetes.

[26]  Terho Lehtimäki,et al.  Branched-Chain and Aromatic Amino Acids Are Predictors of Insulin Resistance in Young Adults , 2013, Diabetes Care.

[27]  Peter Nowotny,et al.  Mechanism of amino acid-induced skeletal muscle insulin resistance in humans. , 2002, Diabetes.

[28]  Michael J. Pencina,et al.  Trends in the Incidence of Type 2 Diabetes Mellitus From the 1970s to the 1990s: The Framingham Heart Study , 2006, Circulation.

[29]  Susan Cheng,et al.  Metabolite Profiling Identifies Pathways Associated With Metabolic Risk in Humans , 2012, Circulation.

[30]  E. Bartoli,et al.  The significance of impaired fasting glucose versus impaired glucose tolerance: importance of insulin secretion and resistance. , 2003, Diabetes care.

[31]  S. Carr,et al.  Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. , 2011, The Journal of clinical investigation.

[32]  Andrea Natali,et al.  α-Hydroxybutyrate Is an Early Biomarker of Insulin Resistance and Glucose Intolerance in a Nondiabetic Population , 2010, PloS one.

[33]  Mark D. Huffman,et al.  Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.

[34]  C. Kahn,et al.  Bidirectional modulation of insulin action by amino acids. , 1998, The Journal of clinical investigation.

[35]  V. Fuster,et al.  Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood Thrombogenicity , 2003, Circulation.

[36]  I. Berlin.  Smoking-induced metabolic disorders: a review. , 2008, Diabetes & metabolism.

[37]  R. Sherwood,et al.  Higher circulating bile acid concentrations in obese patients with type 2 diabetes , 2013, Annals of clinical biochemistry.

[38]  A. Karter,et al.  Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. , 2004, Diabetes.

[39]  R. Vasan,et al.  Metabolite Profiles During Oral Glucose Challenge , 2013, Diabetes.

[40]  Jiantong Wang,et al.  Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004. , 2009, American journal of epidemiology.

[41]  A. Peters,et al.  Identification of Serum Metabolites Associated With Risk of Type 2 Diabetes Using a Targeted Metabolomic Approach , 2013, Diabetes.

[42]  Jussi Paananen,et al.  Hyperglycemia and a Common Variant of GCKR Are Associated With the Levels of Eight Amino Acids in 9,369 Finnish Men , 2012, Diabetes.

[43]  B. Zinman,et al.  Are Metabolically Healthy Overweight and Obesity Benign Conditions? , 2013, Annals of Internal Medicine.

[44]  Gabi Kastenmüller,et al.  Early Metabolic Markers of the Development of Dysglycemia and Type 2 Diabetes and Their Physiological Significance , 2013, Diabetes.

[45]  Tuija Tammelin,et al.  Metabolic Signatures of Insulin Resistance in 7,098 Young Adults , 2012, Diabetes.

[46]  Gretchen A. Casazza,et al.  Improved Metabolic Health Alters Host Metabolism in Parallel with Changes in Systemic Xeno-Metabolites of Gut Origin , 2014, PloS one.

[47]  Patrice D Cani,et al.  The role of the gut microbiota in energy metabolism and metabolic disease. , 2009, Current pharmaceutical design.

[48]  H. Daniel,et al.  Increased Plasma Citrulline in Mice Marks Diet-Induced Obesity and May Predict the Development of the Metabolic Syndrome , 2013, PloS one.

[49]  J. Chiang,et al.  Glucose and Insulin Induction of Bile Acid Synthesis , 2011, The Journal of Biological Chemistry.

[50]  R. Vasan,et al.  2-Aminoadipic acid is a biomarker for diabetes risk. , 2013, The Journal of clinical investigation.

[51]  Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. , 1999, Lancet.